Shanghai, 2018.11.20. Elpiscience announced today that it has submitted an Investigational New Drug (IND) application to the Center of Drug Evaluation (CDE) in Beijing to support the initiation of a Phase I clinical trial of ES101 in China.
ES101, the most leading asset in Elpiscience R&D pipeline, is a first-in-class bispecific antibody targeting PD-L1 and 4-1BB, its PD-L1 dependent 4-1BB activation allows for robust anti-tumor immune activation and lower toxicity concerns in preclinical models.
Dr. Darren Ji, co-founder and CEO of Elpiscience, said “We are delighted to see that ES101, a promising immunotherapeutic bispecific antibody, meets a vital milestone, and we will work closely with the government authorities and clinical centers to move forward ES101 to clinical trials. Going forward, we plan to submit one to two IND applications each year, aspiring to continually bring novel medicines to serve the unmet medical needs.”
ES101 is a tetravalent bispecific antibody that contains four binding domains, two targeting PD-L1 and two targeting 4-1BB, with a molecular weight being only two-thirds of that of a conventional antibody. Based on high PD-L1 expression in the tumor microenvironment and ES101’s unique antibody engineering, ES101 can conditionally activate 4-1BB upon binding to PD-L1. This would allow for more efficient and targeted tumor killing by immune cells.